Shares of EpiCept Co. (NASDAQ:IMNP) traded down 7.1% on Wednesday . The stock traded as low as $0.25 and last traded at $0.26. 4,380 shares were traded during mid-day trading, a decline of 100% from the average session volume of 1,170,404 shares. The stock had previously closed at $0.28.
Several analysts have recently weighed in on the company. ValuEngine raised EpiCept from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Maxim Group set a $2.00 price objective on EpiCept and gave the company a “buy” rating in a research note on Tuesday, April 3rd.
The company has a quick ratio of 0.76, a current ratio of 0.31 and a debt-to-equity ratio of 0.15.
EpiCept (NASDAQ:IMNP) last posted its quarterly earnings data on Tuesday, May 15th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.20) by $0.05.
EpiCept Company Profile
Immune Pharmaceuticals Inc, a clinical stage biopharmaceutical company, develops therapeutic agents in the fields of immuno-inflammation, dermatology, and immuno-oncology. The company's lead product candidate is bertilimumab, a clinical-stage human antibody, which is in Phase II clinical trial that targets eotaxin-1 for the treatment of bullous pemphigoid, crohn's, and ulcerative colitis diseases.
Receive News & Ratings for EpiCept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EpiCept and related companies with MarketBeat.com's FREE daily email newsletter.